Skip to main content Skip to search Skip to main navigation

ICH: Q3D(R2) for elemental impurities reaches Step 2

The draft for the ICH Q3D(R2) Guideline for Elemental Impurities has reached Step 2 on September 25, 2020 and thus the consultation phase. The draft guideline includes, amongst others, corrected PDE values for gold, silver and nickel and a new appendix for impurities that are applied cutaneously or transcutaneously.  

What is regulated by the guideline?  

The ICH Q3D guideline is intended to control elemental impurities and establishes PDE (Permitted Daily Exposure) values for 24 elements. These apply to medicinal products that can be ingested orally, parenterally and via inhalation.  

What is new?  

In revision Q3D(R2), the newly added Appendix 5 also defines limits for impurities in medicinal products that are absorbed cutaneously or transdermally. A basic approach based on a modifying factor (Cutaneous PDE) is presented.  

The PDE values for the following elements in Appendix 2 have been corrected:  

  • Gold (Au): The oral and parenteral PDE was increased from 100 µg/day to 300 µg/day and from 1 µg/day to 3 µg/day for inhalation. 
  • Silver (Ag): The parenteral PDE was increased from 10 to 15 µg/day.  
  • Nickel (Ni): The PDE for inhalation has been increased from 5 µg/day to 6 µg/day.  

This also results in new values for the permitted concentration in µg/g for the respective elements. They are to be used when the content of elemental impurities in medicinal products does not exceed the daily dose of 10 grams per day.  

Furthermore, the monographs for gold and silver in Appendix 3 have been adjusted.  

The draft document is now available for public consultation. The ICH has focused on extracts of the passages that have been revised:

  • Part 1 – Appendix 2 extract : Correction of PDEs for gold, silver and nickel  
  • Part 2 – Appendix 3 extract: Correction of gold monograph  
  • Part 3 – Appendix 3 extract: Correction of silver monograph 
  • Part 4 – new Annex 5 for risk assessment of preparations applied cutaneously and transcutaneuosly 

All proposed changes are marked in red letters.  

The ICH has prepared a summarizing presentation for all changes, which provides a good overview. 


Source: 

ICH: ICH Guideline For Elemental Impurities Q3d(R2) Draft Version 

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

ICH: Updated Q9(R1) Briefing Pack

ICH: Updated Q9(R1) Briefing Pack

The ICH has fully revised the Q9(R1) Briefing Pack (March/April 2026) to align with the updated ICH Q9 guideline.
Read more
EMA: New Plans for the EU GMP Guide

EMA: New Plans for the EU GMP Guide

EMA published the GMDP Inspectors Working Group’s new 2026-2028 work plan and its 2025 annual report.
Read more
EMA: Pharmaceutical Quality System (PQS) Effectiveness Pilot Project

EMA: Pharmaceutical Quality System (PQS) Effectiveness Pilot Project

EMA launched a pilot under which EEA GMP inspectors will assess how sites demonstrate the effectiveness of their pharmaceutical quality system for risk-based change management, and whether the EEA GMP certificate could serve as the main evidence of this effectiveness.
Read more
EMA: Updated Guideline on Active Substance Chemistry

EMA: Updated Guideline on Active Substance Chemistry

The EMA has updated guidance on the information required for the manufacture and control of active substances used in medicinal products, with a 1 September 2026 date of application.
Read more
EMA: Q&A on the Implementation of 3DP Technology for Solid Oral Dosage Forms

EMA: Q&A on the Implementation of 3DP Technology for Solid Oral Dosage Forms

EMA added a new GMP/Q&A section on its website and published a dedicated Q&A document on 3D printing (3DP) for solid oral dosage forms.
Read more
Microbiological Monitoring – Sources of Contamination

Microbiological Monitoring – Sources of Contamination

All pharmaceutical dosage forms must be manufactured under controlled microbiological conditions. This requires microbial monitoring. This applies not only to sterile manufacturing, but also to facilities that manufacture non-sterile products.
Read more
Previous
Next